[go: up one dir, main page]

HUP0104339A2 - Eljárás porckárosodások kezelésére - Google Patents

Eljárás porckárosodások kezelésére

Info

Publication number
HUP0104339A2
HUP0104339A2 HU0104339A HUP0104339A HUP0104339A2 HU P0104339 A2 HUP0104339 A2 HU P0104339A2 HU 0104339 A HU0104339 A HU 0104339A HU P0104339 A HUP0104339 A HU P0104339A HU P0104339 A2 HUP0104339 A2 HU P0104339A2
Authority
HU
Hungary
Prior art keywords
cartilage damage
treating cartilage
gaba analog
medicinally
things
Prior art date
Application number
HU0104339A
Other languages
English (en)
Inventor
Denis Schrier
Howard Glenn Welgus
David Jürgen Wustrow
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of HU0104339D0 publication Critical patent/HU0104339D0/hu
Publication of HUP0104339A2 publication Critical patent/HUP0104339A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

A találmány tárgya eljárás a porckárosodás megelőzésére vagykezelésére, mely abból áll, hogy a kezelendő szervezetbe egy GABAanalógot vagy gyógyászati szempontból alkalmazható sóját juttatják.Ilyen GABA analóg többek között az (I) általános képletű vegyület,ahol R1 jelentése hidrogénatom vagy egyenes vagy elágazó,rövidszénláncú alkilcsoport és n jelentése 4-6 közötti egész szám. Ó
HU0104339A 2000-10-17 2001-10-16 Eljárás porckárosodások kezelésére HUP0104339A2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24111900P 2000-10-17 2000-10-17

Publications (2)

Publication Number Publication Date
HU0104339D0 HU0104339D0 (en) 2001-12-28
HUP0104339A2 true HUP0104339A2 (hu) 2003-12-29

Family

ID=22909333

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104339A HUP0104339A2 (hu) 2000-10-17 2001-10-16 Eljárás porckárosodások kezelésére

Country Status (10)

Country Link
US (2) US6620829B2 (hu)
EP (1) EP1199072A3 (hu)
JP (2) JP3874403B2 (hu)
KR (2) KR100427003B1 (hu)
AU (1) AU780283B2 (hu)
CA (1) CA2358802A1 (hu)
HU (1) HUP0104339A2 (hu)
IL (1) IL145878A0 (hu)
NZ (1) NZ514738A (hu)
ZA (1) ZA200108494B (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
EP1099443A1 (en) 1999-11-11 2001-05-16 Sulzer Orthopedics Ltd. Transplant/implant device and method for its production
CN1625393A (zh) * 2002-01-31 2005-06-08 沃纳-兰伯特公司 治疗耳鸣的α2δ配体
WO2003074048A1 (en) * 2002-03-01 2003-09-12 Warner-Lambert Company Llc Method of treating osteoarthritis
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US8173162B2 (en) * 2003-02-26 2012-05-08 Zimmer Orthobiologics, Inc. Preparation for repairing cartilage tissue, especially articular cartilage defects
WO2005013888A2 (en) * 2003-05-14 2005-02-17 Cytokinetics, Inc. Compounds, compositions and methods
WO2005002585A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
EP1764117A1 (en) 2005-09-20 2007-03-21 Zimmer GmbH Implant for the repair of a cartilage defect and method for manufacturing the implant
US7727978B2 (en) * 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
JP5867730B2 (ja) * 2010-06-29 2016-02-24 国立研究開発法人産業技術総合研究所 ハロゲン化物の検出剤、並びにそれを検出する方法及び検出センサー
RU2679407C1 (ru) * 2013-12-18 2019-02-08 Новассе Са Аналоги гамма-аминомасляной кислоты (гамк) для лечения боли и других заболеваний
US10123983B2 (en) * 2015-09-14 2018-11-13 Washington University DNA methyltransferases for the treatment and prevention of arthritis
CN108358799B (zh) * 2018-04-24 2020-11-10 贵州师范大学 一种普瑞巴林的制备方法
CN116660430B (zh) * 2023-05-16 2023-11-17 正大制药（青岛）有限公司 一种盐酸环苯扎林缓释胶囊的检测方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
JPS6036413A (ja) 1983-08-09 1985-02-25 Kaneshiro Nagai 炎症治癒促進剤
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5358964A (en) * 1993-07-26 1994-10-25 Warner-Lambert Company Benzylidene-lactone and their thiocarbonyl analogs as inhibitors of proteoglycan degradation
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
ATE361909T1 (de) 1996-10-23 2007-06-15 Warner Lambert Co Substituierte gamma-aminobuttersäurederivate als arzneimittel
HRP980342A2 (en) 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
US6329429B1 (en) 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
US6127418A (en) 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
CN1282319A (zh) 1997-10-09 2001-01-31 小野药品工业株式会社 氨基丁酸衍生物
KR20010033154A (ko) 1997-12-16 2001-04-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 제약물로서의 신규한 아민
CN1131855C (zh) 1997-12-16 2003-12-24 沃尼尔·朗伯公司 1－取代－1－氨基甲基－环烷衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途
NZ503980A (en) 1997-12-16 2002-09-27 Warner Lambert Co 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (= gabapentin analogues), pharmaceuticals thereof, and their use in the treatment of neurological disorders
WO1999037296A1 (en) 1998-01-23 1999-07-29 Warner-Lambert Company Gabapentin and its derivatives for the treatment of muscular and skeletal pain
US6506785B2 (en) * 1998-05-22 2003-01-14 Pfizer, Inc. Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives
KR20010043831A (ko) 1998-05-26 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 칼슘 채널의 알파2델타 서브유닛에 대한 친화력이 있는구조적으로 한정된 아미노산 화합물
SK287247B6 (sk) 1999-06-10 2010-04-07 Warner-Lambert Company Llc Kyselina (3S,5R)-3-aminometyl-5-metyloktánová, jej použitie na výrobu liečiva a farmaceutický prostriedok s jej obsahom
HN2000000224A (es) 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos

Also Published As

Publication number Publication date
JP2002167329A (ja) 2002-06-11
AU7937801A (en) 2002-04-18
KR100427003B1 (ko) 2004-05-06
KR20040010497A (ko) 2004-01-31
KR20020030732A (ko) 2002-04-25
AU780283B2 (en) 2005-03-10
JP2006348042A (ja) 2006-12-28
HU0104339D0 (en) 2001-12-28
US20040097405A1 (en) 2004-05-20
EP1199072A2 (en) 2002-04-24
US6620829B2 (en) 2003-09-16
ZA200108494B (en) 2003-04-16
EP1199072A3 (en) 2003-03-19
CA2358802A1 (en) 2002-04-17
NZ514738A (en) 2003-08-29
JP3874403B2 (ja) 2007-01-31
US7189747B2 (en) 2007-03-13
IL145878A0 (en) 2002-07-25
US20020072533A1 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
HUP0104339A2 (hu) Eljárás porckárosodások kezelésére
ATE247464T1 (de) Neue fettanaloge zur behandlung der fettleibigkeit
HUP0400914A2 (hu) Eljárások mitokondriális betegségek kezelésére
DE60220422D1 (de) Substituierte pyrazoloverbindungen zur behandlung von entzündungen
HUP0101137A2 (hu) Véralvadást gátló savamidin-származékok és gyógyászati alkalmazásuk
HUP0301120A2 (hu) Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények
WO2001022953A3 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE69940508D1 (de) Verfahren und zusammensetzung zur behandlung epidermaler irritationen und infektionen
ATE250063T1 (de) Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen
ATE287731T1 (de) Inhibition von histondeacetylase zur behandlung von herzhypertrophie
ATE369845T1 (de) Behandlung der nebenwirkungen von statinen
HK1065941A1 (en) Use of a nicotinic acid alkyl ester containing an alkyl chain from 8 to 22 carbon atoms for the preparation of a medicament for increasing leptin levels in a subject
EP1163208A4 (en) CASPASE INHIBITORS AND THEIR USE
TWI265929B (en) Triazinyl derivatives for inhibiting the production of IL-12
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
DE60327557D1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
ATE274608T1 (de) Säureätzlösung und verfahren zur behandlung von kupfer
ATE363474T1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
MA27257A1 (fr) Composes utiles pour le traitement du charbon et l'inhibition du gene letal
DE60211746D1 (de) Aminosäurederivate zur behandlung der alzheimer-krankheit
DE69816244D1 (de) Verwendung von 2-Aryl-3-aroylbenzo(b)thiophene zur Behandlung des Oestrogenenthaltungssyndroms
SI1077694T1 (en) Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
DE60322343D1 (de) Spermidin derivate zur behandlung chronischer neurodegerenativer krankheiten
HUP0101428A2 (hu) Ciszteinproteázgátlót tartalmazó gyógyszerkészítmény agyszöveti károsodás megelőzésére és kezelésére

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees